- **Brooks Laboratories is a pharmaceutical company built on sterile injectables - the kind of medicines that go directly into a patient’s bloodstream in hospitals, where there is no room for contamination. It was incorporated in 2002 and its plant in Baddi, Himachal Pradesh, started commercial production in June 2006, and it spent its first two decades quietly supplying critical-care drugs to institutions and export markets. The recurring idea that explains its shape is a drive to move up the value chain: first by partnering with a global specialist to enter the tightly regulated carbapenem antibiotics market, then by building its own branded sales force to reach Indian hospitals directly, and always by trying to make more of its own raw materials rather than buying them in.** # Business segments Three engines at different stages - a contract-manufacturing and export base, a branded domestic injectables platform, and a carbapenem joint venture built for regulated markets - each one a step closer to the patient and to higher regulatory barriers. ## 1. Sterile injectables manufacturing: the factory that funds everything else **A WHO-GMP-compliant plant at Baddi makes a wide range of injectable medicines for critical care, earning revenue by selling to other companies, institutions and export markets - this is the volume engine.** - **One plant, many dosage forms** - the Baddi facility produces Beta lactam tablets and dry syrups, general and dry powder injections, eye and ear drops, oncology products and hormonal injections, all under one roof. - **Contract manufacturing is a key contributor** - the company operates a CDMO (Contract Development and Manufacturing Organization) and third-party business, meaning it makes sterile injectables for other pharmaceutical companies, which is a major part of consolidated revenue. - **Exports to semi-regulated markets** - international sales go mainly to countries across Africa, Latin America and the Middle East - including Yemen, Nigeria, Guatemala, Sudan and DR Congo - through partnerships and spot tender opportunities rather than long-term supply contracts. - **R&D focused on making existing processes cheaper** - the in-house lab works on improving yields and cutting reaction times rather than discovering new molecules, and key inventions are protected by patent filings. ## 2. Critical Care Division: the company’s own face to Indian hospitals **A branded injectables business with a 140-person sales force that sells directly to hospitals - built from scratch since 2018 to reduce dependence on low-margin tender business.** - **From B2B to B2C in one move** - before 2018, Brooks sold almost entirely to institutions and through tenders; the Critical Care Division (CCD) was created to put its own brands into hospitals via a dedicated distribution network. - **A sales force deployed across India** - roughly 140 qualified medical sales professionals cover the country, though the southern states were not part of the initial rollout; by FY22 the team was active in Maharashtra, Gujarat, Rajasthan, Uttar Pradesh, Orissa and Chhattisgarh. - **Four product categories under one umbrella** - the CCD portfolio is organised into critical care medicines, broad-spectrum antibiotics, pain management and nutritional products, and an ophthalmic range of eye drops, with about 70 brands launched since 2019. - **50% annual growth since launch** - the Critical Care division’s approximately 70 brands launched since 2019 achieved a compounded annual sales growth rate of 50%, and the company’s stated ambition was to get half of all sales from its own marketing team rather than from third-party or tender channels. ## 3. Brooks Steriscience: the carbapenem bet on regulated markets **A joint venture with a Strides Pharma affiliate that owns a USFDA-approved plant in Vadodara making carbapenem antibiotics - the high-barrier, high-stakes engine aimed at the US and Europe.** - **Carbapenems are last-line antibiotics** - these drugs treat severe, multi-drug-resistant bacterial infections and represent a global market worth over $2 billion, with very few manufacturers having dedicated facilities approved for regulated markets. - **The partner brought money and know-how** - Steriscience Specialties Private Limited (SSPL), majority-owned by Strides Pharma Science, invested Rs. 114.49 crores into the venture, while Brooks contributed the Vadodara plant debt-free. - **Backward-integrated from the start** - the Vadodara site will include an API (active pharmaceutical ingredient) facility for carbapenems, so the venture will make both the drug substance and the finished injection internally, reducing reliance on Chinese or other foreign API suppliers. - **First US approval came in 2022** - the venture received USFDA approval for Meropenem injection (a generic version of Pfizer’s Merrem®) in August 2022, and had already secured marketing authorisation in the UK three months earlier. - **Filings in over 50 countries** - as of September 2025, the venture had product dossiers submitted across more than 50 markets, and a distribution agreement with Armas Pharmaceuticals to supply carbapenems in the United States and Puerto Rico. # Group structure and partners **Brooks Laboratories is the listed parent with one operating plant, while its carbapenem business sits in a jointly controlled associate - and that structure is in motion.** - Brooks Laboratories Ltd directly owns and operates the Baddi manufacturing facility and reports as a single pharmaceuticals segment. - SteriBrooks Penems Private Limited was the original front-end marketing entity for the carbapenem JV; under a 2021 restructuring, its product rights and dossiers were to be transferred to BSL and the entity was to be dissolved, though it remained a jointly controlled entity as of March 2025. - A composite amalgamation scheme announced in September 2025 proposed merging SSPL into BSL and then BSL into OneSource Specialty Pharma Limited (a listed biologics CDMO), which would have consolidated the carbapenem facility under a larger injectables platform, but BSL’s board decided in May 2026 not to pursue the scheme in its current form. - In July 2026, Brooks incorporated a new wholly owned subsidiary, Abridge Speciality Limited, for pharmaceutical manufacturing and marketing, though it had not yet begun operations.